|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1967-10-12
|
|
pubmed:abstractText |
1. The 24 hourly excretion of pyruvate and glucose has been measured in alloxan-diabetic rats.2. The animals were allowed a 6-day control period before being injected with alloxan (I.V. 50 mg/kg body weight). The diabetes was treated by daily injections of insulin for a period of 6 days from the 7th to the 12th day following the alloxan injection.3. The pyruvate excretion increased more than 5-fold following the induction of diabetes, the values being 189 +/- 130 (S.D.) mug/24 hr in the control period rising to an average of 1002 +/- 664 (S.D.) mug/24 hr over the first 6 days of diabetes. The administration of insulin over the second 6-day period of diabetes caused the pyruvate excretion to decrease-though not significantly. Upon the withdrawal of the insulin treatment the pyruvate excretion increased significantly from 785 +/- 315 (S.D.) mug/24 hr to 2105 +/- 679 (S.D.) mug/24 hr, measured over a 5-day period. The final period of pyruvate excretion was significantly greater than the excretion over the first diabetic period.4. The glucose excretion during the initial diabetic period was 6.75 +/- 2.64 (S.D.) g/24 hr. The administration of insulin caused a 42% decrease in glucose excretion compared to a decrease of 22% for the pyruvate. The withdrawal of insulin caused the glucose excretion to increase by 149% while the pyruvate excretion increased by 157%.5. Diabetes was also induced temporarily by injections of anti-insulin serum and diazoxide. In each case significant glycosuria and hyperpyruvaturia were produced.6. The possible causes of the hyperpyruvaturia in diabetes are discussed.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13125618,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13229997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13283052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13464070,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13525392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13683211,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13742271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13758638,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13774931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13794293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13861233,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-13893331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14201155,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14205360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14207897,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14210687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14452345,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14470069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14814149,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14907768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-14938380,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-4158956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-4284560,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-4286307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-5826524,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-5907145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6034113-5965335
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-3751
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
189
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
237-46
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:6034113-Animals,
pubmed-meshheading:6034113-Diabetes Mellitus, Experimental,
pubmed-meshheading:6034113-Diazoxide,
pubmed-meshheading:6034113-Female,
pubmed-meshheading:6034113-Glycosuria,
pubmed-meshheading:6034113-Immune Sera,
pubmed-meshheading:6034113-Insulin, Long-Acting,
pubmed-meshheading:6034113-Pyruvates,
pubmed-meshheading:6034113-Rats
|
|
pubmed:year |
1967
|
|
pubmed:articleTitle |
Hyperpyruvaturia in experimental diabetes.
|
|
pubmed:publicationType |
Journal Article
|
